Loading clinical trials...
Loading clinical trials...
A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-HBV in healthy adult volunteers and participants with hepatitis B virus (HBV).
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
Yes
Research Site 5
Camperdown, New South Wales, Australia
Research Site 4
Clayton, Victoria, Australia
Research Site 3
Melbourne, Victoria, Australia
Research Site 6
Nedlands, Western Australia, Australia
Research Site 7
Hong Kong, Hong Kong
Research Site 1
Grafton, Auckland, New Zealand
Research Site 2
Papatoetoe, Auckland, New Zealand
Start Date
March 27, 2018
Primary Completion Date
April 23, 2020
Completion Date
April 23, 2020
Last Updated
October 22, 2025
114
ACTUAL participants
ARO-HBV
DRUG
Sterile Normal Saline (0.9% NaCl)
OTHER
JNJ-56136379
DRUG
Lead Sponsor
Arrowhead Pharmaceuticals
NCT07024641
NCT06671093
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07275554